N-(t-butoxycarbonyl)-2-nitro-4-(dimethyl-t-butylsiloxy)aniline | 219519-20-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(t-butoxycarbonyl)-2-nitro-4-(dimethyl-t-butylsiloxy)aniline
• 英文别名: tert-butyl N-[4-[tert-butyl(dimethyl)silyl]oxy-2-nitrophenyl]carbamate
• CAS: 219519-20-7
• 化学式: C₁₇H₂₈N₂O₅Si
• 分子量: 368.505
• InChiKey: MDWIBNXHXAJEHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.33
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  93.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(t-butoxycarbonyl)-2-nitro-4-(dimethyl-t-butylsiloxy)aniline 在 四丁基氟化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 Methyl 2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]-3-nitrophenoxy]acetate
  参考文献：
  名称：

  Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors

  摘要：

  We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 mu M) and in vivo antithrombotic efficacy. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.132
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 4-(叔-丁基二甲基硅烷基)氧基-2-硝基苯胺 在 碳酸氢钠 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 N-(t-butoxycarbonyl)-2-nitro-4-(dimethyl-t-butylsiloxy)aniline
  参考文献：
  名称：

  Antithrombotic agents

  摘要：

  这种应用涉及到式(I)的化合物，该化合物的药用盐或其前药，如本文所定义的，以及其药物组合物，以及其作为Xa因子抑制剂的用途，以及其制备方法和中间体。

  公开号：

  US06417200B1

文献信息

• Antithrombotic agents
  申请人：Eli Lilly and Company

  公开号：US06417200B1

  公开（公告）日：2002-07-09

  This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

  这种应用涉及到式(I)的化合物，该化合物的药用盐或其前药，如本文所定义的，以及其药物组合物，以及其作为Xa因子抑制剂的用途，以及其制备方法和中间体。
• Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors
  作者：Kenji Yoshikawa、Toshiharu Yoshino、Yoshihiro Yokomizo、Kouichi Uoto、Hiroyuki Naito、Katsuhiro Kawakami、Akiyoshi Mochizuki、Tsutomu Nagata、Makoto Suzuki、Hideyuki Kanno、Makoto Takemura、Toshiharu Ohta

  DOI：10.1016/j.bmcl.2011.01.132

  日期：2011.4

  We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 mu M) and in vivo antithrombotic efficacy. (C) 2011 Elsevier Ltd. All rights reserved.